
Laurus Labs Ltd. share price
NSE: LAURUSLABS · Healthcare
₹2,220.00 -8.42%
Closing price data, updated 17 Nov 2026. 52-week range: -10.8% from high, +141.8% above low.
Price₹2,220.00
Market cap₹1,19,949 Cr
P/E89.5
P/B19.79
ROE18.2%
ROCE19.5%
Debt / equity0.48
Dividend yield0.00%
EPS₹24.80
Book value₹112.17
Operating margin19.4%
Dipscan score39 / 100
Share: WhatsAppX / TwitterTelegram
Laurus Labs Ltd. shareholding pattern
As of Sep 2026: Promoters 27.47%, FIIs 30.84%, DIIs 11.86%, Government 0.00%, Public 20.03%, Others 9.81%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 27.47% | 27.47% | 27.49% | 27.49% | 27.59% | 27.59% |
| FIIs | 30.84% | 28.00% | 25.82% | 26.52% | 26.16% | 25.70% |
| DIIs | 11.86% | 13.74% | 13.97% | 12.43% | 11.73% | 11.94% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 20.03% | 20.49% | 21.24% | 22.64% | 23.33% | 23.12% |
| Others | 9.81% | 10.30% | 11.47% | 10.92% | 11.18% | 11.65% |
| No. of Shareholders | 311,892 | 291,653 | 292,281 | 280,756 | 283,678 | 280,223 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -8.42% | -5.13% | +8.99% | +19.89% | +68.76% | +125.22% |
Growth
| Sales growth, 3 years | +3.8% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +4.0% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company has been maintaining a healthy dividend payout of 19.0%
Weaknesses
- Stock is trading at 19.8 times its book value
- The company has delivered a poor sales growth of 7.19% over past five years.
- Company has a low return on equity of 10.4% over last 3 years.
- Company might be capitalizing the interest cost
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
| Mankind Pharma Ltd. | ₹2,626.60 | ₹1,08,490 Cr | 48.4 | 12.5% | +18.3% |
Frequently asked questions
What is the share price of Laurus Labs Ltd.?
Laurus Labs Ltd. (LAURUSLABS) last closed at ₹2,220.00 (-8.42% on the day).
What is the market cap of Laurus Labs Ltd.?
About ₹1,19,949 Cr.
What is the P/E ratio of Laurus Labs Ltd.?
The price-to-earnings ratio is 89.5, and return on equity is 18.2%.
Figures are calculated from company results and exchange prices and are for information only.